Physician profile
Erika E Mabus Carper
NPI 1043650401
$646.78
in general payments reported to CMS, 2019-2025
12 companies · $170 in 2025
The $170 reported for 2025 was less than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $38.01 · 2021: $39.74 · 2022: $117 · 2023: $77.93 · 2024: $204 · 2025: $170.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $452.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $452.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Oyster Point Pharma, INC. | $230.91 | 2022-2025 | Tyrvaya |
| Alcon Vision LLC | $131.04 | 2019-2025 | Eysuvis, Precision7, Total30 |
| Kala Pharmaceuticals, INC. | $56.46 | 2021-2022 | |
| Tarsus Pharmaceuticals, INC. | $56.07 | 2025 | Xdemvy |
| Coopervision INC. | $34.38 | 2022-2024 | Myday Contact Lens |
| Sun Pharmaceutical Industries INC. | $28.05 | 2022-2025 | |
| Johnson & Johnson Vision Care, INC. | $26.23 | 2019-2024 | |
| Bausch & Lomb Americas INC. | $23.42 | 2025 | Infuse |
| Lkc Technologies, INC. | $17.86 | 2025 | |
| Dompe US, INC. | $15.03 | 2025 | Oxervate |
| Novartis Pharmaceuticals Corporation | $13.77 | 2021 | |
| Abbvie INC. | $13.56 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erika Mabus Carper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.